# inMMyCAR (NCT07075185)

> A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07075185
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Kelonia Therapeutics, Inc.
- Conditions: Multiple Myeloma in Relapse; Myeloma Multiple; Multiple Myeloma Progression; Neoplasms by Histologic Type; Neoplasm; Hemostatic Disorders; Vascular Disorder; Paraproteinemias; Blood Protein Disorders; Hematologic Disease and Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Disease; Gene Therapy
- Interventions: KLN-1010
- Enrollment: 70
- Primary outcome: Incidence and severity of treatment-emergent adverse events (TEAEs), including dose-limiting toxicities (DLTs), and/or establish the recommended Phase 2 Dose

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 29
- YouTube: 8
- Podcasts: 1
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=inmmycar-nct07075185

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07075185", "email": "<work email>"}; the inbox owner confirms by the emailed link.